Fighting Intensifies For China’s Hepatitis B Drug Market
This article was originally published in PharmAsia News
China is the largest market for hepatitis B drugs due to the huge population at risk. Hepatitis B drugs can be classified into interferon and nucleotide products. Interferon products enjoy high brand recognition: Roche and Schering-Plough account for 52.3 percent of the hospital market, with Roche's Pegasys monopolizing 36.3 percent market share and hitting 108 percent growth in 2007. Most local firms only manage to each grab 6-7 percent of the business. For nucleotide drugs, imported and domestic products have an even fight: GSK tops the list for its lamivudine and adefovir dipivoxil, followed by Bristol-Myers Squibb and Novartis. Due to GSK's inability to get a patent for adefovir dipivoxil in China, 54 domestic organizations are applying to the State FDA for registration of products based on the drug, heating up the competition. (Click here for more - Chinese language)
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.